Research progress of HER2 ultra-low expression breast cancer

doi:10.3760/cma.j.cn371439-20250225-00007

Abstract

Abstract:

Current clinical research and practice have indicated that patients with low human epidermal growth factor receptor 2 （HER2） expression breast cancer can experience therapeutic advantages from treatments with novel antibody-drug conjugates （ADCs）. HER2 ultra-low expression in breast cancer is characterized by an immunohistochemical score of 0， with ≤10% of invasive tumor cells showing incomplete or faint membrane staining. This subgroup constitutes approximately 10%-15% of all breast cancer cases. In comparison to HER2-low expression， tumors with HER2 ultra-low expression display certain differences in clinicopathological characteristics， treatment responses， and prognostic outcomes. Paying attention to HER2 ultra-low expression status and taking corresponding measures can enable these patients to achieve better clinical efficacy.

Key words: Breast neoplasms, Genes， erbB-2, Gene expression, Antibody-drug conjugate

Liu Xinlei, Li Yaru, Chen Shuning, Tang Shenghao, Qin Yan, Liu Yankui, Qi Xiaowei. Research progress of HER2 ultra-low expression breast cancer[J]. Journal of International Oncology, 2026, 53(1): 53-56.

References 26

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690.
[3]	Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial[J]. Nat Med, 2022, 28(9): 1840-1847. DOI: 10.1038/s41591-022-01935-8. pmid: 35941372
[4]	Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis[J]. Cancer Discov, 2022, 12(12): 2754-2762. DOI: 10.1158/2159-8290.Cd-22-0837. pmid: 36255231
[5]	朱军, 黄美金, 李媛, 等. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240. DOI: 10.3760/cma.j.cn371439-20221230-00046.
[6]	Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[J]. J Clin Oncol, 2023, 41(22): 3867-3872. DOI: 10.1200/JCO.22.02864.
[7]	刘月平, 薛卫成, 杨文涛, 等. 乳腺癌HER2低表达病理检测进展及挑战[J]. 中华病理学杂志, 2022, 51(9): 799-802. DOI: 10.3760/cma.j.cn112151-20220620-00542.
[8]	《乳腺癌HER2检测指南(2024版)》编写组. 乳腺癌HER2检测指南(2024版)[J]. 中华病理学杂志, 2024, 53(12): 1192-1202. DOI: 10.3760/cma.j.cn112151-20241009-00664.
[9]	Venetis K, Crimini E, Sajjadi E, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer[J]. Front Mol Biosci, 2022, 9: 834651. DOI: 10.3389/fmolb.2022.834651.
[10]	Wu S, Yue M, Zhang J, et al. The role of artificial intelligence in accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in breast cancer[J]. Mod Pathol, 2023, 36(3): 100054. DOI: 10.1016/j.modpat.2022.100054.
[11]	Shi JJ, Zhang LQ, Geng CZ. HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study[J]. Front Oncol, 2023, 13: 1210314. DOI: 10.3389/fonc.2023.1210314.
[12]	Hatami E, Fanaei SM, Hasteh F, et al. 162 HER2-ultra low and HER2-null breast cancers, incidence and correlation with clinicopathologic parameters[J]. Lab Invest, 2025, 105(3 Sup): 102386. DOI: 10.1016/j.labinv.2024.102386.
[13]	Ahuja S, Khan AA, Zaheer S. Understanding the spectrum of HER2 status in breast cancer: from HER2-positive to ultra-low HER2[J]. Pathol Res Pract, 2024, 262: 155550. DOI: 10.1016/j.prp.2024.155550.
[14]	Bardia A, Hu XC, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer[J]. N Engl J Med, 2024, 391(22): 2110-2122. DOI: 10.1056/NEJMoa2407086.
[15]	Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38(17): 1887-1896. DOI: 10.1200/jco.19.02318.
[16]	Xiao T, Ali S, Mata DGMM, et al. Antibody-drug conjugates in breast cancer: ascent to destiny and beyond—a 2023 review[J]. Curr Oncol, 2023, 30(7): 6447-6461. DOI: 10.3390/curroncol30070474.
[17]	Andrikopoulou A, Zografos E, Liontos M, et al. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer[J]. Clin Breast Cancer, 2021, 21(3): e212-e219. DOI: 10.1016/j.clbc.2020.08.006.
[18]	Anderson Cancer Center. Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer[EB/OL]. (2025-02-10) [2025-02-12]. https://clinicaltrials.gov/study/NCT05633979?cond=HER2%20ULTRA%20LOW&term=Breast%20Cancer&rank=2.
[19]	Zhang J. Different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer (GALAXY)[EB/OL]. (2023-06-27) [2025-02-12]. https://clinicaltrials.gov/study/NCT05824325?cond=HER2%20ULTRA%20LOW&term=Breast%20Cancer&rank=1.
[20]	Chen ZX, Jia HQ, Zhang HN, et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients[J]. Breast Cancer Res Treat, 2023, 202(2): 313-323. DOI: 10.1007/s10549-023-07079-8.
[21]	Tuluhong D, Li XF, Gao HY, et al. Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy[J]. Eur J Cancer Prev, 2023, 32(4): 377-387. DOI: 10.1097/cej.0000000000000813. pmid: 37302017
[22]	Yue M, Wu S, Wang XR, et al. RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1[J]. Pathol Res Pract, 2023, 247: 154532. DOI: 10.1016/j.prp.2023.154532.
[23]	Corné J, Quillien V, Godey F, et al. Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer[J]. Mol Oncol, 2024, 18(11): 2714-2729. DOI: 10.1002/1878-0261.13592.
[24]	Morsberger L, Pallavajjala A, Long P, et al. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry[J]. Cancer Cell Int, 2022, 22(1): 350. DOI: 10.1186/s12935-022-02761-1.
[25]	赵熙萌, 张燕香, 马同辉, 等. 下一代测序技术在癌症诊疗中的应用及研究进展[J]. 药学进展, 2023, 47(6): 404-416. DOI: 10.20053/j.issn1001-5094.2023.06.002.
[26]	Jiang C, Li M, Zheng CY, et al. Systematic analysis of factors affecting human epidermal growth factor receptor 2 interpretation consistency: staining protocols, artificial intelligence-based image standardization, and classification criteria[J]. Lab Invest, 2025, 105(6): 104134. DOI: 10.1016/j.labinv.2025.104134.